#40M SERIES SALESFORCE SLACK FUND VENTURESWIGGERSVENTUREBEAT TRIAL#
“The initiation of the Phase 1 trial for ADX-914 represents an important achievement and a significant step toward bringing a powerful new treatment option to patients with autoimmune disease.
“The closing of our Series B financing and entry into the clinic are pivotal milestones for Q32 Bio,” Q32 Bio CEO Michael Broxson said in a statement. As part of the funding, Isaac Manke of Acorn Bioventures and Diyong Xu of OrbiMed Advisors will join the Q32 Bio board. Other investors in the Series B round included Osage University Partners, Atlas Venture, Abingworth, Sanofi Ventures, University of Colorado and Children’s Hospital Colorado Center for Innovation. That treatment is expected to enter clinical trials in late 2021. The company is also working on another antibody, ADX-097, to provide tissue-targeted regulation. The ADX-914 antibody was developed to re-regulate and restore healthy immune regulation in numerous autoimmune and inflammatory diseases. The Series B funds will be used to support development of ADX-914, Q32 Bio said, as well as support growth of its pipeline and platform. The latest funding comes about five months after Cambridge, Massachusetts-based Q32 emerged from stealth with a $46 million Series A funding round. Q32 Bio, a biotech startup working on treatments for autoimmune and inflammatory diseases, on Thursday announced the close of a $60 million Series B funding led by OrbiMed Advisors and Acorn Bioventures and said it has started Phase 1 clinical trials of its ADX-914 antibody. Q32 raises $60M Series B to fight autoimmune diseases The company said it is anticipating sharp growth in business in 20, based on forecasts for a double-digit rebound for global tourism after the pandemic resolves, traveler confidence increases, and pent-up demand is unlocked.įounded in 2009, GetYourGuide says it has extended offerings to travelers from over 170 countries, who have booked more than 45 million tours, activities and attraction tickets through its platform to date.
Searchlight Capital led the financing round, joined by a consortium of GetYourGuide’s existing investors.
Germany’s GetYourGuide, an online platform for booking tours and travel activities, announced that it raised €114 million ($133 million) in a convertible note financing. Subscribe to the Crunchbase Daily GetYourGuide lands $133M note Here’s what you need to know today in startup and venture news, updated by the Crunchbase News staff throughout the day to keep you in the know.
0 kommentar(er)
